Clinical measures will be performed at randomization, at 2 and 4 weeks as well as at the follow up assessments. A trained rater who is blind to treatment type will administer all measures. Raters will be required to maintain >90% reliability on the primary outcome assessments on ratings with 6 monthly assessments based on videotaped interviews.